Abstract:Gut microbiota is explicitly associated with the development of depressive disorder. However, the molecular pathogenesis associated with gut microbiota with MDD remains unclear. Shugan granule (SGKL), a Chinese patent medicine, is a potential anti‐depression drug via gut microbiota, but the molecular therapeutic mechanism of SGKL remains unknown for the depression process. Our previous study determined SGKL might contribute to alleviating depression symptoms through the PI3K/Akt/mTOR pathway. There is a lack of the investigation to demonstrate whether SGKL can target PI3K/Akt/mTOR pathway based on altered gut microbiota, leading to the improvement of depression progression. We showed a novel mechanism of gut microbiota in causing depression; gut microbiota cause changes in phosphorylation of the PI3K/Akt/mTOR pathway, which mediates microglial activation and subsequent inflammation, eventually causing the development of depression. Importantly, SGKL treatment targets the PI3K/Akt/mTOR pathway in improving depression‐like behaviour, microglia activation, and inflammation. Moreover, we concluded that Parasutterella, Aeromonas, Ruminococcaceae_UCG_008, Globiocatella, Shuttleworthia, and Clostridium_sensu_stricto_1 were the biomarkers of depression, and Candidatus Arthromitus might be the therapeutic target of SGKL during improving depressive‐like behaviours. These findings suggests that SGKL may be the reliable and rational drug for the treatment in depression. Aim The investigation aims to evaluate the potential effect of Shugan Granule (SGKL) on the gut, brain, and behaviors in rats exposed to chronic restraint stress (CRS). Methods The fecal microbiota and metabolite changes were studied in rats exposed to CRS and treated with SGKL (0.1 mg/kg/day). Depressive behaviors of these rats were determined through an open‐field experiment, forced swimming test, sucrose preference, and weighing. Moreover, LPS‐stimulated microglia and CRS‐stimulated rats were treated with SGKL to investigate the regulation between SGKL and the PI3K/Akt/pathway, which is inhibited by LY294002, a PI3K inhibitor. Results (i) SGKL improved the altered behaviors in CRS‐stimulated rats; (ii) SGKL ameliorated the CRS‐induced neuronal degeneration and tangled nerve fiber and also contributed to the recovery of intestinal barrier injury in these rats; (iii) SGKL inhibited the hippocampus elevations of TNF‐α, IL‐1β, and IL‐6 in response to CRS modeling; (iv) based on the principal coordinates analysis (PCoA), SGKL altered α‐diversity indices and shifted β‐diversity in CRS‐stimulated rats; (v) at the genus level, SGKL decreased the CRS‐enhanced abundance of Bacteroides; (vi) Butyricimonas and Candidatus Arthromitus were enriched in SGKL‐treated rats; (vii) altered gut microbiota and metabolites were correlated with behaviors, inflammation, and PI3K/Akt/mTOR pathway; (viii) SGKL increased the LPS‐decreased phosphorylation of the PI3K/Akt/mTOR pathway in microglia and inhibited the LPS‐induced microglial activation; (ix) PI3K/Akt/mTOR pathway inactivation reversed the SGKL effects in CRS rats. Conclusion SGKL targets the PI3K/Akt/mTOR pathway by altering gut microbiota and metabolites, which ameliorates altered behavior and inflammation in the hippocampus.

Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia

Investigation of the Antidepressant Effects of Shu-Gan-Jie- Yu Granule and Its Mechanism of Action

Randomized, Double Blind, Placebo-Controlled Trial of Shuganjieyu Capsule in the Treatment of Mild or Moderate Depression

Efficacy and safety of double doses of SHUGANJIEYU capsules in treating moderate depressive disor-der:a multicenter, random, double-blind, and parallel-controlled trial

Improve Cognition of Depressive Patients Through the Regulation of Basal Ganglia Connectivity: Combined Medication Using Shuganjieyu Capsule.

Effectiveness and safety of modified 'Huoxue Shugan' formulas on coronary heart disease combined with depression: protocol for a systematic review.

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

Evaluation of therapeutic markers and mechanism of Shuganjieyu capsule in treatment of depression

Effectiveness and safety of Jiuwei Zhenxin granules for treating generalized anxiety disorder: A randomized controlled trial

Xiangshao Granules reduce the aggressive behavior and hippocampal injury of premenstrual irritability in rats by regulating JIK/JNK/p38 signal pathway

A Randomized, Controlled Clinical Trial of Combining Therapy with Traditional Chinese Medicine-Based Psychotherapy and Chinese Herbal Medicine for Menopausal Women with Moderate to Serious Mood Disorder

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John’s Wort for Major Depressive Disorder with Somatic Complaints

Efficacy of Shuganjieyu Capsule for Treatment of Neurologic Disorders Combined with Depression: A Meta-Analysis

Proteomics Study Reveals the Anti-Depressive Mechanisms and the Compatibility Advantage of Chaihu-Shugan-San in a Rat Model of Chronic Unpredictable Mild Stress

Shugan granule contributes to the improvement of depression‐like behaviors in chronic restraint stress‐stimulated rats by altering gut microbiota

Plasma metabolomics and network pharmacology identified glutamate, glutamine, and arginine as biomarkers of depression under Shuganjieyu capsule treatment

Combined fractional anisotropy and subcortical volumetric deficits in patients with mild-to-moderate depression: Evidence from the treatment of antidepressant traditional Chinese medicine

Zishen Pingchan Granules Combined with Pramipexole in the Improvement of Depressive Symptoms in Parkinson's Disease: a Prospective, Multicenter, Randomized, Double-Blind, Controlled Clinical Study

Efficacy and Safety of Ganyushu Granule in Treatment of Premenstrual Syndrome with Gan (Liver) Depression and Qi Stagnation Syndrome: A Randomized, Double-Blind, Multi-Center, Phase-II Clinical Trial